TACE plus sorafenib for the treatment of hepatocellular carcinoma: Final results of the multicenter SOCRATES trial.

Erhardt, A.; Kolligs, FT; Dollinger, Matthias; Schott, Eckart; Wege, Henning; Bitzer, Michael; Gog, C.; Raedle, Jochen; Schuchmann, M.; Walter, Clemens; Blondin, D.; Ohmann, Christian; Haeussinger, D.

doi:10.1200/jco.2011.29.15_suppl.4107

Cited by 8 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to anti-angiogenic properties of sorafenib, there is a strong rationale to associate this therapy with TACE. Overall, the START, the SOCRATES and others Phase II trials have shown that the combination of TACE and sorafenib is overall safe and have promising efficacy [35][36][37][38][39].…”

Section: Hepatocellular Carcinomamentioning

confidence: 99%

Sorafenib: 10 years after the first pivotal trial

Gadaleta-Caldarola¹,

Infusino²,

Divella

et al. 2015

Future Oncol.

View full text Add to dashboard Cite

Sorafenib is an oral multikinase inhibitor with anticancer activity against a wide spectrum of cancers. It is currently approved for the treatment of patients with hepatocellular carcinoma, advanced renal cell carcinoma or progressive, locally advanced or metastatic differentiated thyroid carcinoma. In this review, we present a number of studies that investigated the efficacy and safety of sorafenib in these settings. We also discuss the perspectives on the use of this molecule, including the role of sorafenib as comparator for the development of new drugs, the combination of sorafenib with additional therapies (such as transarterial chemoembolization for hepatocellular carcinoma) and the use of this treatment in several other advanced refractory solid tumors.

show abstract

Section: Hepatocellular Carcinomamentioning

confidence: 99%

Sorafenib: 10 years after the first pivotal trial

Gadaleta-Caldarola¹,

Infusino²,

Divella

et al. 2015

Future Oncol.

View full text Add to dashboard Cite

show abstract

“…Erhardt presented a trial with a similar, interrupted design, but enrolled 45 treatment naive patients and performed lipiodolization rather than embolization [13]. Erhardt presented a trial with a similar, interrupted design, but enrolled 45 treatment naive patients and performed lipiodolization rather than embolization [13].…”

mentioning

confidence: 99%

TACE with or without systemic therapy?

Dufour

2012

Journal of Hepatology

View full text Add to dashboard Cite

“…Preclinical models combining transarterial embolization with antiangiogenic agents reported a reduction in tumor volume and vessel density, as well as a prolongation in survival compared with transarterial embolization alone [ 46 ]. In nonrandomized phase II studies, sorafenib concomitant with TACE or doxorubicin-eluting beads (DEB) TACE was well tolerated and effective in unresectable HCC [ 47 – 51 ]. In a phase III randomized trial, sorafenib when given after TACE did not significantly increase time to progression or OS in patients who responded to TACE, potentially due to delays in starting sorafenib after TACE (median 9 weeks) and/or low daily sorafenib doses [ 52 ].…”

Section: Discussionmentioning

confidence: 99%

Multidisciplinary Management of Hepatocellular Carcinoma in Clinical Practice

Bruera

Cannita

Giordano

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

Background. Hepatocellular carcinoma (HCC) patients require different treatment strategies according to disease extension, liver function, and patient's fitness. We evaluated HCC multidisciplinary management in clinical practice. Methods. Consecutive patients were followed and treated with tailored medical, locoregional, and surgical treatments, according to disease stage and patient's fitness (age, Cumulative Illness Rating Scale (CIRS)). Activity, efficacy, and safety were evaluated. Results. Thirty-eight patients were evaluated: median age, 74; elderly 92%; CIRS secondary 28 (74%); Child-Pugh A 20 (53%), B 11 (29%); and Barcelona Clinic Liver Cancer (BCLC) 0 2 (5%), A 9 (24%), B 10 (26%), C 13 (34%), and D 4 (11%). Overall survival (OS) was 30 months. At 9 months median follow-up, among 25 unresectable HCC, OS was 10 months; BCLC B–D unfit for sorafenib showed OS 3 months. Ten patients (40%) received sorafenib: Child-Pugh A 5 (50%) and B 5 (50%) and disease control rate 89%, progression-free survival 7 months, and OS 9 months. G3-4 toxicities: anorexia, hypertransaminaemia, hyperbilirubinemia, and hypercreatininemia. Limiting toxicity syndromes were 40%, all multiple sites. Conclusion. HCC patients require multidisciplinary clinical management to properly select tailored treatments according to disease stage, fitness, and liver function. Patients suitable for sorafenib should be carefully selected, monitored for individual safety, and prevalently characterized by limiting toxicity syndromes multiple sites.

show abstract

TACE plus sorafenib for the treatment of hepatocellular carcinoma: Final results of the multicenter SOCRATES trial.

Cited by 8 publications

References 0 publications

Sorafenib: 10 years after the first pivotal trial

Sorafenib: 10 years after the first pivotal trial

TACE with or without systemic therapy?

Multidisciplinary Management of Hepatocellular Carcinoma in Clinical Practice

Contact Info

Product

Resources

About